Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8643 |
High Similarity |
NPD7266 |
Discontinued |
0.8529 |
High Similarity |
NPD3027 |
Phase 3 |
0.8264 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8214 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8214 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8209 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8188 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8074 |
Intermediate Similarity |
NPD1091 |
Approved |
0.805 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7985 |
Intermediate Similarity |
NPD1357 |
Approved |
0.795 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7929 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7923 |
Intermediate Similarity |
NPD228 |
Approved |
0.7888 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7857 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.784 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7834 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7744 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7742 |
Intermediate Similarity |
NPD37 |
Approved |
0.7708 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7708 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7707 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7707 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7707 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7687 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7669 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7636 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7616 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7607 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7606 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7594 |
Intermediate Similarity |
NPD7843 |
Approved |
0.759 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.758 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7576 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7566 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.753 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7517 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7468 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7468 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7456 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7447 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7426 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7424 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7417 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7394 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7381 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7378 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7378 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7368 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7329 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7324 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7324 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7324 |
Intermediate Similarity |
NPD4749 |
Approved |
0.732 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7315 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7315 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7315 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7305 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7286 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7286 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7285 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7267 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7254 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.725 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.723 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.723 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7212 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7191 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD4237 |
Approved |
0.719 |
Intermediate Similarity |
NPD3060 |
Approved |
0.719 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7152 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7133 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7127 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7118 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.709 |
Intermediate Similarity |
NPD290 |
Approved |
0.7089 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7081 |
Intermediate Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7069 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7069 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7069 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7059 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7059 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7055 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7044 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7044 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7037 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7037 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7037 |
Intermediate Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7035 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7032 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7032 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7029 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7025 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD52 |
Approved |
0.7021 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.6994 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6987 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6987 |
Remote Similarity |
NPD2677 |
Approved |
0.6986 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6971 |
Remote Similarity |
NPD7906 |
Approved |
0.697 |
Remote Similarity |
NPD291 |
Approved |
0.6968 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6966 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6966 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD7028 |
Phase 2 |
0.6954 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6954 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6954 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.695 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6949 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6946 |
Remote Similarity |
NPD6071 |
Discontinued |
0.6943 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD3122 |
Phase 3 |
0.6941 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6939 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6936 |
Remote Similarity |
NPD7313 |
Approved |
0.6936 |
Remote Similarity |
NPD7312 |
Approved |
0.6936 |
Remote Similarity |
NPD7310 |
Approved |
0.6936 |
Remote Similarity |
NPD7311 |
Approved |
0.6933 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD5846 |
Approved |
0.6923 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD6696 |
Suspended |
0.6903 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6899 |
Remote Similarity |
NPD1774 |
Approved |
0.6897 |
Remote Similarity |
NPD7309 |
Approved |
0.6894 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6892 |
Remote Similarity |
NPD9494 |
Approved |
0.689 |
Remote Similarity |
NPD2560 |
Approved |
0.689 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.689 |
Remote Similarity |
NPD2563 |
Approved |
0.6887 |
Remote Similarity |
NPD4140 |
Approved |
0.6883 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6879 |
Remote Similarity |
NPD5241 |
Discontinued |
0.6875 |
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD2122 |
Discontinued |
0.6867 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6867 |
Remote Similarity |
NPD3145 |
Approved |
0.6867 |
Remote Similarity |
NPD3144 |
Approved |
0.6864 |
Remote Similarity |
NPD27 |
Approved |
0.6864 |
Remote Similarity |
NPD2489 |
Approved |
0.6863 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6861 |
Remote Similarity |
NPD556 |
Approved |
0.6859 |
Remote Similarity |
NPD4162 |
Approved |
0.6855 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6849 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6848 |
Remote Similarity |
NPD3882 |
Suspended |
0.6846 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6845 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6842 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6842 |
Remote Similarity |
NPD3657 |
Discovery |
0.6828 |
Remote Similarity |
NPD3092 |
Approved |
0.6824 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6818 |
Remote Similarity |
NPD4663 |
Approved |
0.6818 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6815 |
Remote Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6815 |
Remote Similarity |
NPD4535 |
Phase 3 |
0.6815 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6813 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6813 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.681 |
Remote Similarity |
NPD4773 |
Phase 2 |
0.681 |
Remote Similarity |
NPD4772 |
Phase 2 |
0.6807
|
Remote Similarity |
NPD7075 |
Discontinued |